Harvard Apparatus Regenerative Technology
147 articles about Harvard Apparatus Regenerative Technology
-
Harvard Apparatus Regenerative Technology and the McGowan Institute for Regenerative Medicine at the University of Pittsburgh Establish a Research Collaboration to Study the Repair and Regeneration of the Colon following Colectomy
12/18/2023
Harvard Apparatus Regenerative Technology, Inc. announced that it officially executed a sponsored research agreement with Drs. Stephen Badylak, George Hussey and Vincent Anto at the McGowan Institute for Regenerative Medicine, a center of the University of Pittsburgh and UPMC focused on developing regenerative therapies to address organ and tissue failure.
-
Harvard Apparatus Regenerative Technology Schedules Conference Call and Webcast for Q3 2023 Results
11/9/2023
Harvard Apparatus Regenerative Technology, Inc. announced that it will release Q3 2023 financial results on November 13, 2023 and host a conference call and webcast on the same day November 13, 2023 at 9:00 AM ET to discuss financial results and business updates for the third-quarter 2023.
-
Activated University of Michigan as The Second Site for Clinical Trial in Severe Esophageal Disease
8/28/2023
Harvard Apparatus Regenerative Technology, Inc. announced that it officially activated the second site with University of Michigan for its clinical trial as to severe esophageal disease, being its first clinical trial in the United States.
-
Approval of an Orphan Disease Application for its lead product, the Cellspan Esophageal Implant by the European Medicines Agency
8/21/2023
Harvard Apparatus Regenerative Technology, Inc. today announced the Approval of an Orphan Disease Application for its lead product, the Cellspan Esophageal Implant by the European Medicines Agency (EMA).
-
Biostage, Inc. Changes Name to Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN)
7/20/2023
Biostage, Inc. (OTCQB: formerly BSTG) announced today it has changed its corporate name back to Harvard Apparatus Regenerative Technology, Inc. and trade under the OTCQB symbol "HRGN" effective July 20, 2023.
-
Biostage Activated Mayo Clinic as The First Site for Clinical Trial in Severe Esophageal Disease
7/18/2023
Biostage, Inc. today announced that it officially activated the site with Mayo Clinic for its clinical trial as to severe esophageal disease, being its first clinical trial in the United States.
-
Biostage to Host Investor Call - June 13, 2023
6/13/2023
Biostage, Inc., a clinical-stage biotechnology company developing the technology to regenerate organs inside the body to treat severe diseases, including cancer, trauma and birth defects initially in the esophagus and the airway, announced that it will host an investor call on Tuesday, June 20, 2023.
-
Biostage Initiated Study Start-up Activities for Clinical Trial in Severe Esophageal Disease
5/31/2023
Biostage, Inc. a clinical-stage biotechnology company developing the technology to regenerate organs inside the body to treat severe diseases, including cancer, trauma and birth defects initially in the esophagus and the airway, today announced that it initiated start-up activities for its first clinical trial.
-
Biostage Appoints Ron Packard to Board of Directors
4/10/2023
Biostage, Inc. today announced the appointment of Ron Packard as an independent director to its Board of Directors, adding strength in the areas of business innovation, strategy and finance.
-
Biostage Announces $6 Million Financing to Advance Clinical Trial
4/6/2023
Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company") today announced that it has entered into purchase agreements to raise approximately $6 million from new and existing investors in a private placement of its shares of common stock.
-
Biostage Announces Chairman and CEO Transition
3/2/2023
Biostage, Inc. announced that effective as of March 1, 2023, its existing director since November 2021, Mr. Jerry He, was appointed Chairman of the Board and hired as Chief Executive Officer.
-
Biostage Amends CEO Employment Agreement
1/12/2023
Biostage, Inc. today announced that effective as of January 11, 2023, Biostage, Inc. (the Company) entered into an Amended and Restated Employment Agreement (the Amended Agreement) with David Green, the Chief Executive Officer of the Company, to remove the Interim designation from his Chief Executive Officer title effective immediately, and also amend certain terms of Mr. Green's existing Employment Agreement.
-
Biostage Selects IQVIA to Manage its FDA-Approved Clinical Trial in Severe Esophageal Disease, including Cancer
12/28/2022
Biostage, Inc. announced that it had selected IQVIA, a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, as the contract research organization to manage its first clinical trial.
-
New Publication Demonstrates Rapid Esophageal Regeneration using the Biostage Esophageal Implant
12/23/2022
Biostage, Inc. today announced the publication of a paper in the peer-reviewed Journal of Immunology and Regenerative Medicine that describes the early tissue growth and regeneration processes following the implantation of the Biostage Esophageal Implant (BEI) in nine pigs with full circumferential esophageal segmental replacement.
-
Biostage Reports Corporate Highlights and Third Quarter Financial Results
11/14/2022
Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company") today announced its financial results for the three and nine months ended September 30, 2022, and highlighted recent events.
-
Biostage Schedules Conference Call and Webcast for Q3 2022 Results
11/10/2022
Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company") today announced that it will release Q3 2022 financial results on November 14, 2022 and host a conference call and webcast on November 15, 2022 at 9:00 AM ET to discuss financial results and business updates for the third-quarter 2022.
-
Biostage Receives U.S. Patent for Cellularized Patch-Based Scaffolds for Organ Repair
10/25/2022
Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company") today announced the issuance of a U.S. patent that protects the extension of the use of Biostage's technology from hollow tubes to patches.
-
Biostage Announces Appointment of New Chief Financial Officer - Aug 08, 2022
8/8/2022
Biostage, Inc., a cell-therapy biotechnology company with successful first-in-human experience in treating esophageal cancer and FDA approval to commence a clinical trial of the Biostage Esophageal Implant for severe esophageal disease including cancer, announced the appointment of Joseph Damasio as the company's new Chief Financial Officer.
-
Biostage Schedules Conference Call and Webcast for Q2 2022 Results
8/4/2022
Biostage, Inc.today announced that it will release Q2 2022 financial results on August 4, 2022 and host a conference call and webcast on August 5, 2022 at 9:00 AM ET to discuss financial results and business updates for the second-quarter 2022.
-
Biostage Reports Corporate Highlights and Second Quarter 2022 Financial Results
8/4/2022
Biostage, Inc., a cell-therapy biotechnology company with successful first-in-human experience in treating esophageal cancer and FDA approval to commence a clinical trial of the Biostage Esophageal Implant, or BEI, for severe esophageal disease including cancer, announced its financial results and business updates for the second quarter ended June 30, 2022.